Compare Stocks: BIIB, AMGN, GILD, and IONS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$435.87 +2.6%	$415.69	$288.00 ▼ $447.03	$235.64B	0.41	2.75 million shs	811,515 shs
BIIB Biogen	$242.83 +4.0%	$220.49	$138.00 ▼ $244.65	$35.88B	0.09	1.20 million shs	814,660 shs
GILD Gilead Sciences	$155.88 +1.8%	$147.59	$114.02 ▼ $160.51	$193.28B	0.31	6.80 million shs	2.38 million shs
IONS Ionis Pharmaceuticals	$44.88 +1.1%	$51.50	$42.08 ▼ $86.74	$7.46B	0.38	2.65 million shs	769,630 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	-1.75%	+1.76%	+10.19%	+16.03%	+42.21%
BIIB Biogen	+0.36%	+1.77%	+8.34%	+14.92%	+63.27%
GILD Gilead Sciences	-2.00%	+1.75%	+1.97%	+17.49%	+24.64%
IONS Ionis Pharmaceuticals	+3.35%	+1.63%	-0.14%	-16.88%	-39.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$435.87 +2.6%	$415.69	$288.00 ▼ $447.03	$235.64B	0.41	2.75 million shs	811,515 shs
BIIB Biogen	$242.83 +4.0%	$220.49	$138.00 ▼ $244.65	$35.88B	0.09	1.20 million shs	814,660 shs
GILD Gilead Sciences	$155.88 +1.8%	$147.59	$114.02 ▼ $160.51	$193.28B	0.31	6.80 million shs	2.38 million shs
IONS Ionis Pharmaceuticals	$44.88 +1.1%	$51.50	$42.08 ▼ $86.74	$7.46B	0.38	2.65 million shs	769,630 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	-1.75%	+1.76%	+10.19%	+16.03%	+42.21%
BIIB Biogen	+0.36%	+1.77%	+8.34%	+14.92%	+63.27%
GILD Gilead Sciences	-2.00%	+1.75%	+1.97%	+17.49%	+24.64%
IONS Ionis Pharmaceuticals	+3.35%	+1.63%	-0.14%	-16.88%	-39.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.30	Hold	$387.93	-11.00% Downside
BIIB Biogen	2.63	Moderate Buy	$239.96	-1.18% Downside
GILD Gilead Sciences	2.79	Moderate Buy	$159.63	2.40% Upside
IONS Ionis Pharmaceuticals	2.74	Moderate Buy	$88.90	98.08% Upside

Current Analyst Ratings Breakdown

Latest BIIB, AMGN, GILD, and IONS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/20/2026	IONS Ionis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$79.00
10/20/2026	BIIB Biogen	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$250.00 ➝ $310.00
10/20/2026	GILD Gilead Sciences	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$168.00 ➝ $172.00
10/15/2026	IONS Ionis Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	IONS Ionis Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Neutral ➝ Buy	$46.00 ➝ $88.00
10/13/2026	AMGN Amgen	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$388.00 ➝ $378.00
10/12/2026	AMGN Amgen	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Market Perform	$450.00 ➝ $415.00
10/12/2026	BIIB Biogen	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Perform	$220.00
10/12/2026	AMGN Amgen	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Equal Weight	$435.00 ➝ $430.00
10/12/2026	GILD Gilead Sciences	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$164.00
10/12/2026	BIIB Biogen	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Overweight	$210.00 ➝ $300.00

(Data available from 10/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$36.75B	6.41	$34.08 per share	12.79	$16.08 per share	27.11
BIIB Biogen	$9.89B	3.63	$23.62 per share	10.28	$124.45 per share	1.95
GILD Gilead Sciences	$29.44B	6.56	$10.45 per share	14.92	$18.23 per share	8.55
IONS Ionis Pharmaceuticals	$944M	7.90	N/A	N/A	$3.02 per share	14.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$7.71B	$16.09	27.09	17.73	3.17	22.95%	124.14%	13.18%	11/3/2026 (Estimated)
BIIB Biogen	$1.29B	$5.65	42.98	15.20	2.58	8.32%	11.18%	6.88%	10/28/2026 (Estimated)
GILD Gilead Sciences	$8.51B	-$2.67	N/A	15.73	N/A	-10.64%	-2.11%	-0.75%	10/29/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)

Latest BIIB, AMGN, GILD, and IONS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	IONS Ionis Pharmaceuticals	-$1.21	N/A	N/A	N/A	$183.30 million	N/A
11/3/2026	Q3 2026	AMGN Amgen	$5.77	N/A	N/A	N/A	$10.06 billion	N/A
10/29/2026	Q3 2026	GILD Gilead Sciences	$2.18	N/A	N/A	N/A	$7.79 billion	N/A
10/28/2026	Q3 2026	BIIB Biogen	$1.98	N/A	N/A	N/A	$2.63 billion	N/A
8/4/2026	Q2 2026	AMGN Amgen	$5.62	$6.29	+$0.67	$4.37	$9.43 billion	$10.05 billion
8/3/2026	Q2 2026	GILD Gilead Sciences	-$7.25	-$6.75	+$0.50	-$8.45	$7.40 billion	$7.80 billion
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$10.08	2.31%	+8.27%	62.65%	14 Years
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.28	2.10%	+3.04%	N/A	10 Years
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest BIIB, AMGN, GILD, and IONS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/28/2026	GILD Gilead Sciences	quarterly	$0.82	2.24%	9/15/2026	9/15/2026	9/29/2026
7/30/2026	AMGN Amgen	quarterly	$2.52	2.29%	8/21/2026	8/21/2026	9/11/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	4.44	1.37	1.13
BIIB Biogen	0.39	1.87	1.26
GILD Gilead Sciences	2.03	1.27	1.09
IONS Ionis Pharmaceuticals	3.07	7.89	7.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BIIB Biogen	87.93%
GILD Gilead Sciences	83.67%
IONS Ionis Pharmaceuticals	93.86%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.85%
BIIB Biogen	0.25%
GILD Gilead Sciences	0.30%
IONS Ionis Pharmaceuticals	1.81%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	31,500	540.63 million	536.04 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
GILD Gilead Sciences	17,000	1.24 billion	1.24 billion	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable

BIIB, AMGN, GILD, and IONS Headlines

Recent News About These Companies

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock Has Consensus Target Price of $89.14

October 20 at 6:28 AM | marketbeat.com

Ionis Pharmaceuticals (NASDAQ:IONS) EVP Shannon Devers Sells 1,357 Shares of Stock

October 20 at 4:22 AM | insidertrades.com

Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 1,357 Shares of Stock

October 19 at 11:07 PM | marketbeat.com

Ionis Pharmaceuticals (NASDAQ:IONS) versus Upstream Bio (NASDAQ:UPB) Head-To-Head Comparison

October 19 at 6:58 AM | americanbankingnews.com

Analyzing Ionis Pharmaceuticals (NASDAQ:IONS) & Krystal Biotech (NASDAQ:KRYS)

October 19 at 4:45 AM | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Ionis Pharmaceuticals (IONS)

October 17 at 5:27 PM | theglobeandmail.com

UBS upgrades Ionis Pharmaceuticals to buy from neutral

October 17 at 5:27 PM | msn.com

Ionis Pharmaceuticals Receives Approval Recommendation for Tryngolza's Indication Expansion in EU

October 16, 2026 | finance.yahoo.com

Ionis Pharmaceuticals Shares Rise After UBS Upgrade

October 16, 2026 | finance.yahoo.com

CHMP Backs Ionis TRYNGOLZA For Severe Hypertriglyceridemia In Europe

October 16, 2026 | rttnews.com

CHMP Recommends Ioni's TRYNGOLZA Approval For Several Hypertriglyceridemia In EU

October 16, 2026 | rttnews.com

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)

October 16, 2026 | businesswire.com

UBS Upgrades Ionis Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $88 From $46

October 15, 2026 | finance.yahoo.com

Ionis Pharmaceuticals (NASDAQ:IONS) Sets New 12-Month Low - Here's Why

October 13, 2026 | marketbeat.com

Ionis Pharmaceuticals (IONS) Receives a Buy from Bank of America Securities

October 10, 2026 | theglobeandmail.com

Alnylam vs. Ionis: Here's the Better Bad-News Buy

October 10, 2026 | fool.com

Ionis Pharmaceuticals (IONS) After The Pullback Is The Undervalued Narrative Still Intact

October 9, 2026 | finance.yahoo.com

Ionis Pharmaceuticals (IONS) Stock Could Still Trade At A Premium Despite A 46% Slump

October 8, 2026 | uk.finance.yahoo.com

NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido

October 8, 2026 | zacks.com

Ionis Pharmaceuticals (NASDAQ:IONS) Reaches New 52-Week Low - Should You Sell?

October 5, 2026 | marketbeat.com

Consensus price target for Ionis Pharmaceuticals rises 20.88% to MX$1,849.62

October 2, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB, AMGN, GILD, and IONS Company Descriptions

Amgen NASDAQ:AMGN

$435.86 +10.93 (+2.57%)

As of 01:48 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Biogen NASDAQ:BIIB

$242.82 +9.35 (+4.00%)

As of 01:48 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Gilead Sciences NASDAQ:GILD

$155.88 +2.81 (+1.84%)

As of 01:48 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Ionis Pharmaceuticals NASDAQ:IONS

$44.88 +0.50 (+1.13%)

As of 01:48 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BIIB, AMGN, GILD, and IONS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BIIB, AMGN, GILD, and IONS Earnings

Compare Dividends

Latest BIIB, AMGN, GILD, and IONS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BIIB, AMGN, GILD, and IONS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB, AMGN, GILD, and IONS Company Descriptions

Amgen NASDAQ:AMGN

Biogen NASDAQ:BIIB

Gilead Sciences NASDAQ:GILD

Ionis Pharmaceuticals NASDAQ:IONS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BIIB, AMGN, GILD, and IONS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BIIB, AMGN, GILD, and IONS Earnings

Compare Dividends

Latest BIIB, AMGN, GILD, and IONS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BIIB, AMGN, GILD, and IONS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB, AMGN, GILD, and IONS Company Descriptions

Amgen NASDAQ:AMGN

Biogen NASDAQ:BIIB

Gilead Sciences NASDAQ:GILD

Ionis Pharmaceuticals NASDAQ:IONS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools